Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | THRB | P10828 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | CNR2 | P34972 | 5/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14029902 | 0.88 | CNR2 (0.52) | THRBCNR2L3MBTL1RXFP1KMT2A | |
| SCHEMBL14005266 | 0.85 | RAB9A (0.55) | MAPTTHRBCNR2KDM4ERXFP1 | |
| SCHEMBL4745657 | 0.80 | CNR2 (0.76) | CNR2 | |
| SCHEMBL14005262 | 0.77 | HPGDS (0.67) | L3MBTL1 | |
| SCHEMBL14030757 | 0.76 | RAB9A (0.53) | MAPTPOLBCNR2KDM4EKMT2A | |
| SCHEMBL14030749 | 0.75 | ACACB (0.43) | MAPTCNR2KDM4EGAA | |
| SCHEMBL12844507 | 0.73 | NSD2 (0.63) | MAPTKDM4EL3MBTL1KMT2AGAA | |
| SCHEMBL14030760 | 0.72 | KMT2A (0.46) | MAPTKMT2AGAARAB9ANPSR1 | |
| SCHEMBL14030761 | 0.69 | EGLN1 (0.39) | THRBCNR2KMT2ARAB9ANPSR1 | |
| SCHEMBL31680569 | 0.68 | KMT2A (0.89) | L3MBTL1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080293711-A1 | Chemokine receptor modulators | METASTATIX, INC. | 2008-11-27 | — | — | US | disclosed |
| US-20080293711-A1 | Chemokine receptor modulators | METASTATIX, INC. | 2008-11-27 | — | — | US | disclosed |
| WO-2008112156-A1 | CHEMOKINE RECEPTOR MODULATORS | ALTIRIS THERAPEUTICS (US) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293711-A1 | Chemokine receptor modulators | CCR5, CCL2, CXCR4 | MAPT 4253/4885THRB 1846/4885POLB 2589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.